Related Experiment Video

Updated: Mar 18, 2026

Cancer-Associated Fibroblasts from Mouse Mammary Tumors as Tools for Molecular and Computational Studies
09:01

Cancer-Associated Fibroblasts from Mouse Mammary Tumors as Tools for Molecular and Computational Studies

Published on: July 3, 2025

1.1K

JAK-STAT signaling in cancer: From cytokines to non-coding genome

Jan Pencik1, Ha Thi Thanh Pham2, Johannes Schmoellerl3

  • 1Clinical Institute of Pathology, Medical University of Vienna, 1090 Vienna, Austria; Division of Nuclear Medicine, Department of Biomedical Imaging and Image-guided Therapy, 1090 Vienna, Austria; Ludwig Boltzmann Institute for Cancer Research, Medical University of Vienna, 1090 Vienna, Austria.

Cytokine
|June 29, 2016
PubMed

Insights

Janus kinases (JAKs) and signal transducers (STATs) pathways regulate cell functions and are targeted in autoimmune diseases and cancers. Non-coding RNAs add a new regulatory layer, crucial for understanding cancer and improving patient therapy.

Area of Science:

  • Molecular Biology
  • Immunology
  • Oncology

Background:

  • The Janus kinases (JAKs) and signal transducers and activators of transcription (STATs) pathway is a conserved signaling cascade linking cytokine signaling to cellular processes.
  • JAK/STAT pathway dysregulation is implicated in autoimmune diseases and cancer progression.
  • JAK/STAT pathway inhibitors are established treatments for autoimmune conditions and emerging therapies for various cancers.

Purpose of the Study:

  • To review the role of JAK/STAT signaling in cellular mechanisms.
  • To highlight the emerging role of non-coding RNAs in regulating JAK/STAT signaling.
  • To emphasize the therapeutic potential of targeting JAK/STAT and non-coding RNAs in cancer.

Main Methods:

  • Literature review of studies on JAK/STAT signaling.
  • Analysis of the role of non-coding RNAs in JAK/STAT pathway regulation.
  • Discussion of therapeutic strategies targeting JAK/STAT signaling in cancer.

Main Results:

  • JAK/STAT signaling controls proliferation, invasion, survival, inflammation, and immunity.
  • Aberrant JAK/STAT signaling contributes to cancer progression and metastasis.
  • Non-coding RNAs represent novel regulators and potential biomarkers in JAK/STAT-driven cancers.

Conclusions:

  • Non-coding RNAs introduce a new layer of regulation to the JAK/STAT pathway.
  • Understanding non-coding RNA interactions with JAK/STAT signaling is critical for cancer therapy.
  • Targeting JAK/STAT and non-coding RNAs offers promising strategies for cancer treatment and patient stratification.
Keywords:
Hematopoietic malignanciesJAK/STAT signalingNon-coding RNAsProstate cancerSarcomas

More Related Videos

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

896
Merging Absolute and Relative Quantitative PCR Data to Quantify STAT3 Splice Variant Transcripts11:19

Merging Absolute and Relative Quantitative PCR Data to Quantify STAT3 Splice Variant Transcripts

Published on: October 9, 2016

15.6K

Related Concept Videos

The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
13.7K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.0K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

1.6K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
7.8K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
7.3K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

4.2K